Regulation of HIV-Mediated CD4 T Cell Apoptosis

HIV 介导的 CD4 T 细胞凋亡的调节

基本信息

  • 批准号:
    8462016
  • 负责人:
  • 金额:
    $ 45.86万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-04-01 至 2013-12-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): It is well accepted that HIV infection causes an accelerated rate of CD4 T cell apoptosis that contributes to the CD4 T cell losses which occur in an HIV infected patient. It is also well accepted that HIV gp120 can trigger a variety of cell type including CD4 T cells to undergo apoptosis, using signaling pathways that involve P38, JNK, Caspases, and mitochondrial depolarization. Finally it is well accepted that other mechanisms contribute to CD4 T cell loss during HIV disease, including enhanced production of proapoptotic ligands (FasL and TRAIL) by HIV infected macrophages and dendritic cells, microbial translocation across the gut epithelia, and cytotoxic effects of other HIV proteins including Tat, Nef, and Vpr. What remains unknown is whether there is a common mechanism which ties these distinct pathways together. We will present preliminary data in primary CD4 T cells suggest a novel underlying mechanism which links each of these pathways, whereby X4 gp120 signaling through CXCR4 first causes an apoptosis prone phenotype of CD4 T cells by altering the regulation of microRNA, such that Foxo3A is upregulated, and together with JNK (also activated by gp120), Foxo3A is activated, resulting in enhanced transcription of apoptotic regulatory molecules including BIM. This then allows gp120 primed and apoptosis prone cells to undergo apoptosis when they encounter proapoptotic stimuli whether that be FasL, Tat, or more gp120. Of special interest, gp120 stimulation also has the effect of priming CD4 T cells to die following exposure to the bacterial product, LPS by virtue of upregulating the Toll like receptor machinery. Given the pervasive nature of gp120 and its diverse effects on the immune regulation of HIV infected patients, it is of great interest to examine the immune effects of effective CXCR4 inhibition; consequently we will carefully examine both the immune and antiviral effects of a new class of CXCR4 inhibitor which is in clinical development, KRH-1636. Results of the proposed investigations will both inform and increase the understanding of the immunopathogenesis of HIV; how the microbial translocation hypothesis directly causes CD4 T cell loss and the clinical efforts to develop a CXCR4 inhibitor that is free of off-target effects.
描述(由申请人提供):公认的是,艾滋病毒感染导致CD4T细胞凋亡率加快,这是导致艾滋病毒感染者发生的CD4T细胞丢失的原因。HIV gp120还可以通过P38、JNK、Caspase和线粒体去极化等信号通路,触发包括CD4T细胞在内的多种细胞类型的凋亡。最后,人们普遍认为,HIV感染的巨噬细胞和树突状细胞产生的促凋亡配体(FasL和TRAIL)的增加,肠道上皮细胞的微生物移位,以及其他HIV蛋白包括Tat、Nef和VPR的细胞毒作用,都是导致HIV疾病期间CD4T细胞丢失的其他机制。目前尚不清楚的是,是否有一种共同的机制将这些不同的途径联系在一起。我们将提供原代CD4T细胞的初步数据,提示一种新的潜在机制,该机制连接了这些途径中的每一个,其中X4 gp120信号通过CXCR4首先通过改变microRNA的调节而导致易凋亡的CD4T细胞表型,从而FOXO3a被上调,并与JNK(也被gp120激活)一起被激活,导致包括BIM在内的凋亡调控分子的转录增强。这使得gp120启动的和易发生凋亡的细胞在遇到促凋亡刺激时发生凋亡,无论是FasL、TAT还是更多的gp120。特别值得注意的是,gp120刺激还具有通过上调Toll样受体机制,使CD4T细胞在暴露于细菌产物LPS后死亡的效果。鉴于gp120的广泛存在及其对HIV感染患者免疫调节的不同作用,检测有效抑制CXCR4的免疫效果是非常有意义的;因此,我们将仔细研究一类正在临床开发的新型CXCR4抑制剂KRH-1636的免疫和抗病毒效果。拟议的研究结果将提供信息并增加对艾滋病毒免疫发病机制的了解;微生物易位假说如何直接导致CD4T细胞丢失,以及临床努力开发一种无非靶标效应的CXCR4抑制剂。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANDREW D BADLEY其他文献

ANDREW D BADLEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANDREW D BADLEY', 18)}}的其他基金

Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistence.
评估新型细胞凋亡抑制剂 TRAILshort 在维持 HIV 持久性方面的作用。
  • 批准号:
    9272805
  • 财政年份:
    2015
  • 资助金额:
    $ 45.86万
  • 项目类别:
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistence.
评估新型细胞凋亡抑制剂 TRAILshort 在维持 HIV 持久性方面的作用。
  • 批准号:
    8990167
  • 财政年份:
    2015
  • 资助金额:
    $ 45.86万
  • 项目类别:
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistence.
评估新型细胞凋亡抑制剂 TRAILshort 在维持 HIV 持久性方面的作用。
  • 批准号:
    9089882
  • 财政年份:
    2015
  • 资助金额:
    $ 45.86万
  • 项目类别:
Evaluating the role of the novel apoptosis inhibitor TRAILshort, in maintaining HIV persistence
评估新型细胞凋亡抑制剂 TRAILshort 在维持 HIV 持续存在方面的作用
  • 批准号:
    10427482
  • 财政年份:
    2015
  • 资助金额:
    $ 45.86万
  • 项目类别:
Prime shock and kill for HIV erradication
为根除艾滋病毒提供休克和杀戮
  • 批准号:
    8996120
  • 财政年份:
    2014
  • 资助金额:
    $ 45.86万
  • 项目类别:
Prime shock and kill for HIV erradication
为根除艾滋病毒提供休克和杀戮
  • 批准号:
    8657290
  • 财政年份:
    2014
  • 资助金额:
    $ 45.86万
  • 项目类别:
Prime shock and kill for HIV erradication
为根除艾滋病毒提供休克和杀戮
  • 批准号:
    9889021
  • 财政年份:
    2014
  • 资助金额:
    $ 45.86万
  • 项目类别:
Prime shock and kill for HIV erradication
为根除艾滋病毒提供休克和杀戮
  • 批准号:
    10388158
  • 财政年份:
    2014
  • 资助金额:
    $ 45.86万
  • 项目类别:
Enhancing control of HIV by inhibiting TRAILshort
通过抑制 TRAILshort 加强对 HIV 的控制
  • 批准号:
    8698830
  • 财政年份:
    2013
  • 资助金额:
    $ 45.86万
  • 项目类别:
Procaspase 8 Activation by HIV Protease
HIV 蛋白酶激活半胱氨酸蛋白酶原 8
  • 批准号:
    6841913
  • 财政年份:
    2004
  • 资助金额:
    $ 45.86万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 45.86万
  • 项目类别:
    Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 45.86万
  • 项目类别:
    Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 45.86万
  • 项目类别:
    Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 45.86万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 45.86万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 45.86万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 45.86万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 45.86万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 45.86万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 45.86万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了